Skip to main content
Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc. — Investor Relations & Filings

Ticker · JSPR ISIN · US4718712023 US Professional, scientific and technical activities
Filings indexed 422 across all filing types
Latest filing 2019-11-20 Director's Dealing
Country US United States of America
Listing US JSPR

About Jasper Therapeutics, Inc.

https://jaspertx.com/

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies targeting mast and hematopoietic stem cells. The company's lead product candidate is briquilimab, a monoclonal antibody that targets c-Kit (CD117). This therapeutic is designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. Jasper Therapeutics is conducting clinical studies to evaluate briquilimab in patients with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to provide safer and more effective therapies for patients with chronic mast cell-driven diseases.

Recent filings

Filing Released Lang Actions
Director's Dealing 2019
Director's Dealing
2019-11-20 English
Director's Dealing 2019
Director's Dealing
2019-11-20 English
Director's Dealing 2019
Director's Dealing
2019-11-20 English
Director's Dealing 2019
Director's Dealing
2019-11-20 English
Director's Dealing 2019
Director's Dealing
2019-11-20 English
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It includes descriptions of securities, references to registration statements, and exhibits related to certificates of incorporation, bylaws, and specimen certificates. This type of filing is a regulatory announcement related to securities registration and does not contain financial statements, earnings data, or management discussion. It is not an annual report, earnings release, or any other financial report type. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2019-11-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.